Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.67 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326247 | 0.95 | PTPN22 (0.62) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL13056341 | 0.87 | PTPN22 (0.70) | PTPN22PTPN12KMT2AMEN1POLB | |
| SCHEMBL1907110 | 0.86 | PTPN22 (0.53) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL1907114 | 0.86 | PTPN22 (0.53) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL1901690 | 0.84 | PTPN22 (0.61) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL1901689 | 0.84 | PTPN22 (0.61) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL13056344 | 0.84 | PTPN22 (0.70) | PTPN22KMT2AMEN1MAPTPOLB | |
| SCHEMBL1901692 | 0.84 | PTPN22 (0.61) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL10491494 | 0.84 | AKR1B1 (0.79) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL19736246 | 0.84 | AKR1B1 (0.79) | PTPN22PTPN12KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | PTPN22 3261/4885PTPN12 3273/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.